ANDA Submissions Drop To Start FY 2021, Perhaps Forced Down By COVID-19
Executive Summary
First quarter submission volume is the second lowest of the GDUFA era, in part because of BE study problems caused by the pandemic.
You may also be interested in...
ANDA Approval Decline Continues, But Why?
US FDA says COVID disruptions may be having an impact; complete response letters have also dropped significantly.
ANDA Approval Decline Continues, But Why?
US FDA says COVID disruptions may be having an impact; complete response letters have also dropped significantly.
Slump In Generic Submissions Helps US FDA Draw Nearly Even With Approvals
ANDA approval rates have remained steady, while submission rates dropped compared to prior years.